Two patients had at least 98% fewer polyps in the upper digestive tract
Recursion Pharmaceuticals (RXRX) announced positive Phase 1b/2 data for REC-4881, showing a 47% median reduction in polyp burden in FAP patients, with 85% maintaining reductions after 12 weeks off treatment. REC-1245 showed partial responses in cancer patients. Sanofi optioned a development candidate from their collaboration. The company raised $200M, extending its cash runway into 2029.
How this was made
The 30-second read
Why it matters
The financing extends cash runway to 2029, supporting continued development and potentially reducing dilution concerns.
Market read
First‑report of robust Phase 1b/2 results for a rare GI disease, likely to move RXRX and related biotech stocks.
What to watch
Regulatory timeline uncertainty and the need for larger Phase 2/3 data could temper upside.
Background
Recursion announced a $200 million financing round alongside the clinical updates and a Sanofi option deal.
Ticker impact
Recursion (NASDAQ:RXRX) disclosed Phase 1b/2 data showing 55% median polyp burden reduction in upper GI and two patients with ≥98% reduction.
upward pressure as market prices in the strong efficacy signals
Phase 1b/2 results are material for a biotech and indicate progress toward a registrational trial, which typically lifts stock valuations.
Market effects
Positive data may lift other AI‑driven biotech peers and increase interest in GI‑focused therapies.
US biotech sector may see modest gains as investors reassess pipeline prospects.
Limited to biotech investors; no broad market impact.
Counterpoint
If the data are not yet peer‑reviewed, the market could overreact and a later setback would cause a sharp correction.
Key entities
- companyRecursion
AI‑enabled drug discovery firm reporting trial data.
- companySanofi
Partner with option on a potential immunology candidate.
